Lexicon Pharmaceuticals (LXRX) Non-Current Deferred Tax Liability (2010 - 2019)

Lexicon Pharmaceuticals (LXRX) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $6.0 million in Q2 2019.

• Non-Current Deferred Tax Liability for Q2 2019 came in at $6.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2019 was $6.0 million (changed 0.0% YoY), and the FY2018 annual result was $6.0 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $6.0 million in Q2 2019 per LXRX's latest filing, from $6.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $18.7 million in Q1 2015 and troughed at -$18.7 million in Q4 2015.
• A 5-year average of $10.2 million and a median of $10.0 million in 2017 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2015 and 2016: Non-Current Deferred Tax Liability plunged 200.0% in 2015, then jumped 200.0% in 2016.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at -$18.7 million in 2015, then jumped by 200.0% to $18.7 million in 2016, then slumped by 67.8% to $6.0 million in 2017, then changed by 0.0% to $6.0 million in 2018, then changed by 0.0% to $6.0 million in 2019.
• Business Quant data shows LXRX's Non-Current Deferred Tax Liability at $6.0 million in Q2 2019, $6.0 million in Q1 2019, and $6.0 million in Q4 2018.